Current Standing
A clear view of what has been built, what has been received, and what remains in progress.
Four projects are documented alongside barter inventory, cash payments and the ongoing monthly services agreement. Project 1 is settled. Projects 2–4 remain active development projects. August service work is built into the running reconciliation, and the recurring $1,000 monthly service schedule begins in September 2026.
Latest record: August 26, 202601 · Projects
Four separate projects
Project budgets are not presented as payments received. They are shown separately so the relationship can be reconciled clearly.
Original Financial Project
The original project was completed and made whole. Historical Barter Batch 1 was absorbed into this project and is already part of the settled exchange.
Weight Loss Peptides Precision Research
Complete rebrand and development overhaul following the change from the original Affordable GLP-1 Weight Loss Telehealth direction.
Active
Precision Cellular Wellness
Premium website and growth platform including strategy, design, development, SEO, AI optimization, video integration and continued expansion.
Active
PCW Research Peptides
Separate website and brand build including bottle branding, label direction, product presentation, SEO, AI optimization, video integration and expansion.
Active
02 · Received Value
What has been received
Historical Barter Batch 1 is excluded because it was already applied to and absorbed by settled Project 1. The current reconciliation begins with Barter Batch 2 and now includes Barter Batch 5 at the corrected documented value of $1,810.
| Source | Status / Date | Documented Value |
|---|---|---|
| Barter Batch 2 | Priced inventory + 5 TBD glutathione | $3,410+ |
| Barter Batch 3 | Received July 27, 2026 | $3,800 |
| Barter Batch 4 | Received August 1, 2026 | $10,100 |
| Cash Payment 1 | July 24, 2026 | $1,000 |
| Cash Payment 2 | July 28, 2026 | $1,000 |
| TOTAL CURRENTLY PRICED VALUE RECEIVED | $21,120+ | |
03 · Ongoing Agreement
Monthly video, marketing & site care
The service agreement was established August 14, 2026. August work is included in the current reconciliation, with recurring $1,000 monthly payments beginning in September 2026.
Video, Marketing & Site Care
Covers additional video production, ongoing marketing support and continued maintenance/care for PCW Research Peptides and Precision Cellular Wellness.
- Agreement Date August 14, 2026
- August Service Work Included in current amount owed
- Recurring Schedule Begins September 2026
- Monthly Service Going Forward $1,000 at the start of each month
- Sites Covered PCW Research Peptides + Precision Cellular Wellness
Produced & Delivered
All four video production requests have been completed and delivered, including the additional requests dated August 16 and August 20, 2026.
Additional Development
PCW Video Integration & Optimization
Substantial development work was completed across both PCW websites to build out video integration and supporting optimization.
Completed · 2 SitesCurrent Monthly Status
Recurring Billing Starts in September
August service work is included in the current amount owed. The ongoing $1,000 monthly video, marketing and site-care payment begins in September 2026.
$1,000 / Month Starting September04 · Supporting Detail
Inventory & payment records
The detailed line items are kept below for verification without making the top of the page difficult to read.
Barter Batch 2 · $3,410+ currently priced
| Item | Qty | Price Each | Total |
|---|---|---|---|
| GLOW 70 mg | 8 | $70 | $560 |
| BPC-157 / TB-500 20 mg | 8 | $85 | $680 |
| SS-31 50 mg | 3 | $150 | $450 |
| NAD+ 500 mg | 3 | $50 | $150 |
| MOTS-C 40 mg | 3 | $100 | $300 |
| Reduced Glutathione 1.5 g | 5 | TBD | TBD |
| Tirzepatide 10 mg | 1 | $50 | $50 |
| Tirzepatide 20 mg | 6 | $100 | $600 |
| Retatrutide 10 mg | 4 | $80 | $320 |
| Retatrutide 12 mg | 3 | $100 | $300 |
| CURRENTLY PRICED BATCH 2 TOTAL | $3,410+ | ||
Barter Batch 3 · July 27, 2026 · $3,800
| Item | Qty | Price Each | Total |
|---|---|---|---|
| MOTS-C 40 mg | 10 | $75 | $750 |
| SS-31 50 mg | 10 | $150 | $1,500 |
| GHK-CU 100 mg | 10 | $60 | $600 |
| BPC-157 / TB-500 20 mg | 10 | $85 | $850 |
| Bacteriostatic Water 10 mL | 20 | $5 | $100 |
| BATCH 3 TOTAL | $3,800 | ||
Barter Batch 4 · August 1, 2026 · $10,100
| Item | Qty | Price Each | Total |
|---|---|---|---|
| Tesamorelin / Ipamorelin 10 mg / 10 mg | 10 | $90 | $900 |
| Retatrutide 16 mg | 20 | $150 | $3,000 |
| Retatrutide 10 mg | 20 | $80 | $1,600 |
| ARA-290 10 mg | 20 | $50 | $1,000 |
| Kisspeptin 5 mg | 20 | $50 | $1,000 |
| PT-141 | 20 | $50 | $1,000 |
| NAD+ 1000 mg | 20 | $80 | $1,600 |
| BATCH 4 TOTAL | $10,100 | ||
Barter Batch 5 · $1,810 corrected total
Cash Payments · $2,000 total received
| Payment | Date | Method | Amount |
|---|---|---|---|
| Cash Payment 1 | July 24, 2026 | Bank of America transfer | $1,000 |
| Cash Payment 2 | July 28, 2026 | Bank of America transfer | $1,000 |
| TOTAL DOCUMENTED CASH RECEIVED | $2,000 | ||
05 · Reconciliation
Where things stand
A simple visual comparison of the current project range and the value already received.
All bars use the same $0–$75K scale.
Current reconciliation range After applying the $21,120+ already received, and including August service work in the running reconciliation, the approximate remaining project range is:
Recurring service begins September 2026 for PCW Research Peptides and Precision Cellular Wellness.
Historical Barter Batch 1 was already absorbed into Project 1 and should not be counted again. The current $21,120+ received-value reconciliation covers Barter Batches 2, 3, 4 and 5 plus two separate $1,000 Bank of America cash payments. Barter Batch 5 is recorded at $1,810. August service work is included in the running reconciliation rather than shown as a separate August payment. The recurring video, marketing and site-care agreement begins at $1,000 per month starting in September 2026. All four currently documented video production requests have been produced and delivered.